Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
BackgroundCurrent statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline. Methods and ResultsWe compared statin use and dosing between adults >75 an...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cbebc59e4d734dd8ad6bc3524868d19a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cbebc59e4d734dd8ad6bc3524868d19a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cbebc59e4d734dd8ad6bc3524868d19a2021-11-12T17:01:48ZStatin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry10.1161/JAHA.118.0085462047-9980https://doaj.org/article/cbebc59e4d734dd8ad6bc3524868d19a2018-05-01T00:00:00Zhttps://www.ahajournals.org/doi/10.1161/JAHA.118.008546https://doaj.org/toc/2047-9980BackgroundCurrent statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline. Methods and ResultsWe compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary or secondary prevention statin use without considering guideline‐recommended age criteria. The patients were treated at 138 US practices in the Patient and Provider Assessment of Lipid Management (PALM) registry in 2015. Patient surveys also evaluated reported symptoms while taking statins. Multivariable logistic regression models examined the association between older age and statin use and dosing. Among 6717 people enrolled, 1704 (25%) were >75 years old. For primary prevention, use of any statin or high‐dose statin did not vary by age group: any statin, 62.6% in those >75 years old versus 63.1% in those ≤75 years old (P=0.83); high‐dose statin, 10.2% versus 12.3% in the same groups (P=0.14). For secondary prevention, older patients were slightly less likely to receive any statin (80.1% versus 84.2% [P=0.003]; adjusted odds ratio, 0.81; 95% confidence interval, 0.66–1.01 [P=0.06]), but were much less likely to receive a high‐intensity statin (23.5% versus 36.2% [P<0.0001]; adjusted odds ratio, 0.54; 95% confidence interval, 0.45–0.65 [P=0.0001]). Among current statin users, older patients were slightly less likely to report any symptoms (41.3% versus 46.6%; P=0.003) or myalgias (27.3% versus 33.3%; P<0.001). ConclusionsOverall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to receive high‐intensity statins for secondary prevention. Statins appear to be similarly tolerated in older and younger adults.Michael G. NannaAnn Marie NavarTracy Y. WangXiaojuan MiSalim S. ViraniMichael J. LouieL. Veronica LeeAnne C. GoldbergVeronique L. RogerJennifer RobinsonEric D. PetersonWileyarticleagingelderlyprimary preventionsecondary preventionstatinstatin therapyDiseases of the circulatory (Cardiovascular) systemRC666-701ENJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 10 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
aging elderly primary prevention secondary prevention statin statin therapy Diseases of the circulatory (Cardiovascular) system RC666-701 |
| spellingShingle |
aging elderly primary prevention secondary prevention statin statin therapy Diseases of the circulatory (Cardiovascular) system RC666-701 Michael G. Nanna Ann Marie Navar Tracy Y. Wang Xiaojuan Mi Salim S. Virani Michael J. Louie L. Veronica Lee Anne C. Goldberg Veronique L. Roger Jennifer Robinson Eric D. Peterson Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| description |
BackgroundCurrent statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline. Methods and ResultsWe compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary or secondary prevention statin use without considering guideline‐recommended age criteria. The patients were treated at 138 US practices in the Patient and Provider Assessment of Lipid Management (PALM) registry in 2015. Patient surveys also evaluated reported symptoms while taking statins. Multivariable logistic regression models examined the association between older age and statin use and dosing. Among 6717 people enrolled, 1704 (25%) were >75 years old. For primary prevention, use of any statin or high‐dose statin did not vary by age group: any statin, 62.6% in those >75 years old versus 63.1% in those ≤75 years old (P=0.83); high‐dose statin, 10.2% versus 12.3% in the same groups (P=0.14). For secondary prevention, older patients were slightly less likely to receive any statin (80.1% versus 84.2% [P=0.003]; adjusted odds ratio, 0.81; 95% confidence interval, 0.66–1.01 [P=0.06]), but were much less likely to receive a high‐intensity statin (23.5% versus 36.2% [P<0.0001]; adjusted odds ratio, 0.54; 95% confidence interval, 0.45–0.65 [P=0.0001]). Among current statin users, older patients were slightly less likely to report any symptoms (41.3% versus 46.6%; P=0.003) or myalgias (27.3% versus 33.3%; P<0.001). ConclusionsOverall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to receive high‐intensity statins for secondary prevention. Statins appear to be similarly tolerated in older and younger adults. |
| format |
article |
| author |
Michael G. Nanna Ann Marie Navar Tracy Y. Wang Xiaojuan Mi Salim S. Virani Michael J. Louie L. Veronica Lee Anne C. Goldberg Veronique L. Roger Jennifer Robinson Eric D. Peterson |
| author_facet |
Michael G. Nanna Ann Marie Navar Tracy Y. Wang Xiaojuan Mi Salim S. Virani Michael J. Louie L. Veronica Lee Anne C. Goldberg Veronique L. Roger Jennifer Robinson Eric D. Peterson |
| author_sort |
Michael G. Nanna |
| title |
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| title_short |
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| title_full |
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| title_fullStr |
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| title_full_unstemmed |
Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry |
| title_sort |
statin use and adverse effects among adults >75 years of age: insights from the patient and provider assessment of lipid management (palm) registry |
| publisher |
Wiley |
| publishDate |
2018 |
| url |
https://doaj.org/article/cbebc59e4d734dd8ad6bc3524868d19a |
| work_keys_str_mv |
AT michaelgnanna statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT annmarienavar statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT tracyywang statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT xiaojuanmi statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT salimsvirani statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT michaeljlouie statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT lveronicalee statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT annecgoldberg statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT veroniquelroger statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT jenniferrobinson statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry AT ericdpeterson statinuseandadverseeffectsamongadultsgt75yearsofageinsightsfromthepatientandproviderassessmentoflipidmanagementpalmregistry |
| _version_ |
1718430398951718912 |